Despite recent advances in the treatment of human colon cancer, the chemotherapeutic efficacy against colon cancer is still unsatisfactory. The complexity in colorectal cancer treatment leads to new research in combination therapy to overcome multidrug resistance in cancer and increase apoptosis. The objective of the present research work was to develop polyplexes for co-delivery of plasmid DNA with retinoic acid against colorectal cancer cell line (HCT-15). Plain polyplexes were prepared using chitosan and hyaluronic acid solution (0.1% w/v), whereas retinoic acid polyplexes were prepared using ethanol: water (1:9 v/v) system. The particle size was observed in the order of chitosan solution > blank polyplex > retinoic acid-loaded polyplex. Encapsulation efficiency of retinoic acid was found to be 81.51 ± 4.33% for retinoic acid-loaded polyplex formulation. The drug release was observed to be in a controlled pattern with 72.23 ± 1.32% release of retenoic acid from polyplex formulation. Cell line studies of the formulation displayed better cell inhibition and low cytotoxicity for the retinoic acid-loaded polyplexes in comparison to pure retinoic acid, thus demonstrating better potential action against colorectal cancer cell line HCT-15. Retinoic acid-loaded polyplexes indicated higher potential for the delivery of the active whereas the cell line studies displayed the efficacy of the formulation against colorectal cancer cell line HCT-15.

尽管近来在人类结肠癌的治疗方面取得了进展，但针对结肠癌的化学治疗效果仍然不能令人满意。结直肠癌治疗的复杂性导致了联合治疗的新研究，以克服癌症中的多药耐药性并增加细胞凋亡。本研究工作的目的是开发复合体，用于共递送质粒 DNA 与视黄酸对抗结肠直肠癌细胞系 (HCT-15)。使用壳聚糖和透明质酸溶液 (0.1% w/v) 制备普通复合物，而使用乙醇: 水 (1:9 v/v) 系统制备视黄酸复合物。颗粒大小按壳聚糖溶液 > 空白复合物 > 维甲酸负载复合物的顺序观察。发现视黄酸的包封率为 81.51 ± 4。33% 用于载有维甲酸的复合制剂。观察到药物释放处于受控模式，复合制剂中的维甲酸释放率为 72.23 ± 1.32%。与纯维甲酸相比，该制剂的细胞系研究显示，载有维甲酸的复合物具有更好的细胞抑制作用和较低的细胞毒性，因此表明对结肠直肠癌细胞系 HCT-15 具有更好的潜在作用。载有维甲酸的复合物显示了更高的活性物质递送潜力，而细胞系研究显示了该制剂对结肠直肠癌细胞系 HCT-15 的功效。与纯维甲酸相比，该制剂的细胞系研究显示，载有维甲酸的复合物具有更好的细胞抑制作用和较低的细胞毒性，因此表明对结肠直肠癌细胞系 HCT-15 具有更好的潜在作用。载有维甲酸的复合物显示了更高的活性物质递送潜力，而细胞系研究显示了该制剂对结肠直肠癌细胞系 HCT-15 的功效。与纯维甲酸相比，该制剂的细胞系研究显示，载有维甲酸的复合物具有更好的细胞抑制作用和较低的细胞毒性，因此表明对结肠直肠癌细胞系 HCT-15 具有更好的潜在作用。载有维甲酸的复合物显示了更高的活性物质递送潜力，而细胞系研究显示了该制剂对结肠直肠癌细胞系 HCT-15 的功效。